Related Experiment Video
Updated: May 12, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients
Jiyu Sun1, Hyo Jin Lee2, Jung-Kyu Lee2
1Integrated Biostatistics Branch, Division of Cancer Data Science, National Cancer Center, Goyang-si, Republic of Korea.
Background:
The systemic impact of long-term use of inhaled corticosteroid (ICS) on the liver remains poorly understood in patients with chronic obstructive pulmonary disease (COPD). Our study aimed to identify whether long-term ICS therapy impacts the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with COPD.
Methods:
A retrospective cohort study was conducted using claims records from a large population-based database. We included COPD patients ≥40 years old who had no previous history of chronic liver disease. Patients were divided into two groups based on their ICS use. The primary outcome was the development of MASLD. Additionally, subgroup analyses were conducted according to the duration of ICS exposure and the various components of ICS.
Results:
A total of 442,880 COPD patients were included in the study, with 95,695 in ICS group and 347,185 in non-ICS group. The incidence rate of MASLD was higher in the ICS group compared to the non-ICS group (859.3 vs. 440.4 per 100,000 person-years). After adjusting for potential confounding factors, ICS use was associated with a significantly increased risk of MASLD (hazard ratio [HR]=1.630, 95 % confidence interval [CI]=1.560-1.704). Fluticasone furoate showed a higher risk of MASLD compared to other ICS components, and a longer duration of ICS exposure was associated with an increased MASLD risk.
Conclusions:
In COPD patients, long-term use of ICS may be associated with an increased risk of developing MASLD. Further studies are needed to explore strategies to mitigate the potential risk of MASLD in COPD patients requiring ICS therapy.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation